Využití sérových hladin mědi a zinku při diagnostickém hodnocení endometriomu a epiteliálního karcinomu vaječníků

Download PDF English version

Authors: Z. E. Utkan Korun ¹; M. Erdem ²; A. Erdem ²; A. Onan ²; N. Bozkurt ²; M. Öktem ²; K. Biberoğlu ²
Authors‘ workplace: Department of Obstetrics and Gynecology, Acıbadem Maslak Hospital, Istanbul, Turkey ¹; Department of Obstetrics and Gynecology, Gazi University School of Medicine, Ankara, Turkey ²
Published in: Ceska Gynekol 2023; 88(4): 279-286
Category: Original Article
doi: https://doi.org/10.48095/cccg2023279

Overview

Cíl: Cílem této studie je zhodnotit sérové hladiny mědi (Cu) a zinku (Zn) u pacientek s epiteliálním karcinomem ovaria a endometriomem. Materiál a metody: Do studie bylo zařazeno 21 pacientek s epiteliálním karcinomem ovaria, 47 pacientek s endometriomem, 31 zdravých žen v reprodukčním věku a 10 zdravých žen v menopauze. Byly porovnány hladiny Cu a Zn a poměry Cu/Zn. Výsledky: Ve skupině s endometriomem byly hladiny Cu (p = 0,04) a poměr Cu/Zn (p < 0,01) vyšší, zatímco hladiny Zn (p < 0,01) byly nižší ve srovnání s kontrolní skupinou. Prahová hodnota 1,15 s 62% senzitivitou a 61% specificitou byla vypočtena pro poměr Cu/Zn pomocí ROC křivky (AUC = 0,688; p = 0,005). Ve skupině s rakovinou vaječníků byly hladiny Cu (p ≤ 0,01) a poměr Cu/Zn (p = 0,02) vyšší, zatímco hladiny Zn (p ≤ 0,02) byly nižší ve srovnání s kontrolní skupinou. Prahová hodnota poměru Cu/Zn 1,37 byla vypočtena se 76% senzitivitou a 90% specificitou (AUC = 0,829; p = 0,004). Hladina Zn byla nižší (p = 0,02) a poměr Cu/Zn byl vyšší (p = 0,01) ve skupině s karcinomem ovaria ve srovnání se skupinou s endometriomem. Závěr: Prahová hodnota poměru Cu/Zn pro karcinom ovaria mohla být stanovena se specificitou 90 %, zatímco senzitivita a specificita poměru Cu/Zn pro endometriom byly nízké.

Klíčová slova:

karcinom vaječníků – měď – zinek – endometriom – poměr měď zinek

Sources

1. Bulun SE, Yilmaz BD, Sison C et al. Endometriosis. Endocr Rev 2019; 40 (4): 1048–1079. doi: 10.1210/er.2018-00242.

2. Samartzis EP, Labidi-Galy SI, Moschetta M et al. Endometriosis – associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets – a narrative review. Ann Transl Med 2020; 8 (24): 1712. doi: 10.21037/atm-20-3022a.

3. Kobayashi H. Potential scenarios leading to ovarian cancer arising from endometriosis. Redox Rep 206; 21 (3): 119–126. doi: 10.1179/1351000215Y.0000000038.

4. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009; 35 (1): 32–46. doi: 10.1016/j.ctrv.2008.07.004.

5. Yaman M, Kaya G, Simsek M. Comparison of trace element concentrations in cancerous and noncancerous human endometrial and ovary tissues. Int J Gynecol Cancer2007; 17 (1): 220–228. doi: 10.1111/j.1525-1438.2006.00742.x.

6. Michalczyk K, Cymbaluk-Płoska A. The role of zinc and copper in gynecological malignancies. Nutrients 2020; 12 (12): 3732. doi: 10.3390/nu12123732.

7. Kazi Tani LS, Gourlan AT, Dennouni-Medjati N et al. Copper isotopes and copper to zinc ratio as possible biomarkers for thyroid cancer. Front Med (Lausanne) 2021; 8: 698167. doi: 10.3389/fmed.2021.698167.

8. Lin S, Yang H. Ovarian cancer risk according to circulating zinc and copper concentrations: a meta-analysis and Mendelian randomization study. Clin Nutr 2021; 40 (4): 2464–2468. doi: 10.1016/j.clnu.2020.10.011.

9. Cunzhi H, Jiexian J, Xianwen Z et al. Serum and tissue levels of six trace elements and copper/zinc ratio in patients with cervical cancer and uterine myoma. Biol Trace Elem Res 2003; 94 (2): 113–122. doi: 10.1385/BTER: 94: 2: 113.

10. Shobeiri MJ, Tabrizi AD, Atashkhoei S et al. Serum levels of copper, zinc and copper/zinc ratio in patients with ovarian cancer. Pakistan J Med Sci 2011; 27 (3): 561–565.

11. Atakul T, Altinkaya SO, Abas BI et al. Serum copper and zinc levels in patients with endometrial cancer. Biol Trace Elem Res 2020; 195 (1): 46–54. doi: 10.1007/s12011-019-01844-x.

12. Turgut A, Özler A, Görük NY et al. Copper, ceruloplasmin and oxidative stress in patients with advanced-stage endometriosis. Eur Rev Med Pharmacol Sci 2013; 17 (11): 1472–1478.

13. Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short- -term and long-term effectiveness. Am J Obstet Gynecol 1981; 139 (6): 645–654. doi: 10.1016/ 0002-9378 (81) 90478-6.

14. Elmer P, Conn N. Analytical methods for atomic absorption spectrophotometery. London 1975.

15. Application news A634. Direct analysis of metallic elements in cell culture medium by atomic absorption spectrophotometry (AAS). Shimadzu 2020.

16. Hasanbegovic L, Alicelebic S, Sljivo N. Comparison of specific ovarian tumor markers by elecsys analyzer 2010. Acta Inform Med 2015; 23 (2): 86–89. doi: 10.5455/aim.2015.23.86-89.

17. Becker CM, Bokor A, Heikinheimo O et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022; 2022 (2): hoac009. doi: 10.1093/ hropen/hoac009.

18. Testa AC, Timmerman D, van Holsbeke C et al. Ovarian cancer arising in endometrioid cysts: ultrasound findings. Ultrasound Obstet Gynecol 2011; 38 (1): 99–106. doi: 10.1002/uog.8970.

19. van Holsbeke C, van Calster B, Guerriero S et al. Endometriomas: their ultrasound characteristics. Ultrasound Obstet Gynecol 2010; 35 (6): 730–740. doi: 10.1002/uog.7668.

20. Králíčková M, Vetvicka V, Fiala L et al. The search for biomarkers in endometriosis: a long and windy road. Reprod Sci 2022; 29 (6): 1667–1673. doi: 10.1007/s43032-021-00668-2.

21. Lai GL, Yeh CC, Yeh CY et al. Decreased zinc and increased lead blood levels are associated with endometriosis in Asian Women. Reprod Toxicol 2017; 74: 77–84. doi: 10.1016/j.reprotox.2017. 09.001.

22. Lightman A, Brandes JM, Binur N et al. Use of the serum copper/zinc ratio in the differential diagnosis of ovarian malignancy. Clin Chem 1986; 32 (1 Pt 1): 101–103.

23. Okonkwo CA, Amegor FO, Gbolade JO. Relationship between trace elements and major gynaecological malignancies. Asian J Med Sci 2013; 6: 124–127. doi: 10.19026/ajms.5.5347.

24. Marinov B, Tsachev K, Doganov N et al. The copper concentration in the blood serum of women with ovarian tumors (a preliminary report). Akush Ginekol (Sofiia) 2000; 39 (2): 36–37.

25. Brandes JM, Lightman A, Druhan A et al. The diagnostic value of serum copper/zinc ratio in gynecological tumors. Acta Obstet Gynecol Scand 1983; 62 (3): 225–229. doi: 10.3109/00016348309155796.

26. Al Musalhi K, Al Kindi M, Al Aisary F et al. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Med J 2016; 31 (5): 336–344. doi: 10.5001/omj.2016.68.